Effects of Serelaxin in Patients Admitted for Acute Heart Failure: A Meta-Analysis
Article 2019 en
Authors
JT
John R. Teerlink
BD
Beth A. Davison
GC
Gad Cotter
Abstract
1 min read
Administration of intravenous serelaxin to patients admitted for AHF was associated with a highly significant reduction in the risk of 5-day worsening heart failure and in changes in renal function markers, but not length of stay, or cardiovascular death, or heart or renal failure rehospitalization. Serelaxin administration was safe and associated with a significant reduction in all-cause mortality.
Johannes Grand, Kristina Miger, Ahmad Sajadieh, Lars Køber, Christian Torp‐Pedersen, Georg Ertl, José López‐Sendón, Aldo Maggioni, Olav Wendelboe Nielsen
Johannes Grand, Kristina Miger, Ahmad Sajadieh, Lars Køber, Christian Torp‐Pedersen, Georg Ertl, JL. Lopez Sendon, Aldo Maggioni, Olav Wendelboe Nielsen
Johannes Grand, Kristina Miger, Ahmad Sajadieh, Lars Køber, Christian Torp‐Pedersen, Georg Ertl, José López‐Sendón, Aldo Maggioni, John R. Teerlink, Naoki Sato, Claudio Gimpelewicz, Marco Metra, Thomas Holbro, Olav Wendelboe Nielsen
Fabrizio Oliva, Andrea Mortara, Giuseppe Cacciatore, Alessandra Chinaglia, Andrea Di Lenarda, Marco Gorini, Marco Metra, Michele Senni, Aldo Maggioni, Luigi Tavazzi
Discussion(0)
No comments yet. Be the first to comment.